522 related articles for article (PubMed ID: 15319772)
1. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
Erdmann AA; Jung U; Foley JE; Toda Y; Fowler DH
Biol Blood Marrow Transplant; 2004 Sep; 10(9):604-13. PubMed ID: 15319772
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
[TBL] [Abstract][Full Text] [Related]
3. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.
Fowler DH; Breglio J; Nagel G; Hirose C; Gress RE
Biol Blood Marrow Transplant; 1996 Oct; 2(3):118-25. PubMed ID: 9199754
[TBL] [Abstract][Full Text] [Related]
4. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
6. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
Blazar BR; Taylor PA; Fitzsimmons WE; Vallera DA
J Immunol; 1994 Aug; 153(4):1836-46. PubMed ID: 7519216
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
Liu YP; Li Z; Nador RG; Strober S
Transplantation; 2008 Feb; 85(4):607-14. PubMed ID: 18347541
[TBL] [Abstract][Full Text] [Related]
8. Facilitation of parental-strain marrow engraftment by T cells of neonatally-tolerant mice.
Davenport C; George T; Devora GA; Morris MA; Gordon BE; Kumar V; Bennett M
Biol Blood Marrow Transplant; 1997 Dec; 3(6):294-303. PubMed ID: 9502296
[TBL] [Abstract][Full Text] [Related]
9. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
10. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
11. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
Krenger W; Snyder KM; Byon JC; Falzarano G; Ferrara JL
J Immunol; 1995 Jul; 155(2):585-93. PubMed ID: 7608537
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
13. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
15. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
16. B7.2-/- mature dendritic cells generate T-helper 2 and regulatory T donor cells in fetal mice after in utero allogeneic bone marrow transplantation.
Bhattacharyya S; Cowan MJ
Biol Blood Marrow Transplant; 2005 Sep; 11(9):657-71. PubMed ID: 16125636
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
[TBL] [Abstract][Full Text] [Related]
18. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
19. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
20. Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: synergism with veto cells and rapamycin.
Steiner D; Brunicki N; Bachar-Lustig E; Taylor PA; Blazar BR; Reisner Y
Exp Hematol; 2006 Jun; 34(6):802-8. PubMed ID: 16728286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
